Try our Advanced Search for more refined results

IN RE ASACOL ANTITRUST LITIGATION

  1. August 02, 2019

    Allergan To Pay $2.7M To End Certain Generic-Delay Claims

    Allergan will pay a combined $2.7 million and allow judgment to be entered against it to resolve claims from three of the plaintiffs accusing the company's subsidiary of delaying generic competition for Asacol, according to letters filed in Massachusetts federal court Friday.

  2. June 18, 2019

    Asacol Buyers Say Product-Hopping Suit Requires Trial

    Buyers of Allergan's ulcerative colitis drugs have told a Massachusetts federal court that they were coerced into paying for higher-priced medication when the company blocked a generic drug from the market, which they say is enough to push their antitrust case to trial.

  3. May 13, 2019

    Allergan Says Asacol Buyers' Generic-Delay Suit Defective

    Allergan is seeking to end a suit brought by buyers of its ulcerative colitis drug who allege a company subsidiary sought to delay generic competition, telling a Massachusetts federal court the buyers were not forced to buy the drug.

  4. May 03, 2019

    Allergan Says Drug Buyers Trying To Delay Case 'Indefinitely'

    Allergan slammed buyers of its ulcerative colitis drug for indefinitely trying to stay their antitrust suit while a judge reconsiders their bid for class certification, telling a Massachusetts federal court Thursday the case should not be a class action.

  5. April 23, 2019

    Allergan Drug Buyers Take One Last Shot At Class Cert.

    Purchasers of Allergan's ulcerative colitis drug lodged a last-ditch effort for class certification in their antitrust suit, asking a Massachusetts federal judge Monday to reconsider denying them a chance to rework their bid after an appellate court rejected an earlier iteration.

  6. April 12, 2019

    Allergan Drug Buyers' Renewed Bid For Cert. Deemed 'Futile'

    Purchasers of Allergan's ulcerative colitis drug won't get a second crack at class certification in their antitrust suit, as a Massachusetts federal judge has found their renewed effort would likely look the same as the first iteration that an appellate court rejected, rendering it "futile."

  7. March 21, 2019

    1st Circ. Loss Dooms New Asacol Buyer Class, Allergan Says

    Allergan PLC said a group that claims the company's anti-competitive methods caused it to overpay for its ulcerative colitis drug should not get a second chance at class certification after the First Circuit knocked down its first attempt.

  8. March 11, 2019

    Asacol 3rd-Party Payors Want Another Shot At Class Cert.

    Buyers of Allergan's ulcerative colitis drug Asacol asked a Massachusetts federal court Friday for permission to renew their class certification bid after a trip to the First Circuit in their suit alleging the company's anti-competitive activity caused them to overpay for the drug.

  9. March 20, 2018

    Allergan Drug Buyers Urge 1st Circ. To Keep Class Cert.

    A class of purchasers of an anti-inflammatory drug made by Allergan PLC told the First Circuit on Tuesday that a Massachusetts federal judge was right to grant them class certification in their suit claiming the pharmaceutical company illegally stifled generic competition in an effort to keep prices high.

  10. March 06, 2018

    Legal Group Urges 1st Circ. To Flip Asacol Class Cert.

    The Washington Legal Foundation on Monday backed Allergan PLC in a fight over class certification, telling the First Circuit that a Massachusetts federal judge shouldn't have certified a class of insurers who paid for an ulcerative colitis drug without parties tied to each state involved in the product-hopping suit.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!